STA Pharmaceutical Co.’s (WuXi STA) Analytical Service Unit in Shanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two inspections from the U.S. FDA, with no Form 483s issued.    WuXi STA has now successfully passed seven inspections from the U.S. FDA since 2013, producing branded drugs marketed in 95 countries. Its Analytical Service Unit provides analytical method development, validation and testing services fr...